Please ensure Javascript is enabled for purposes of website accessibility

Intercept Pharmaceuticals Reports 40% Revenue Growth for 2019

By Taylor Carmichael – Updated Feb 25, 2020 at 12:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's lead drug, Ocaliva, brought in $249.6 million last year.

Intercept Pharmaceuticals (NASDAQ:ICPT) released its fourth-quarter report on Tuesday, and the among the highlights was an annual revenue figure 40% higher than 2018's result. Ocaliva, the company's primary biliary cholangitis (PBC) drug, brought in $70 million for the quarter and $249.6 million for the year.

Intercept has filed a new drug application with the Food and Drug Administration to expand the label indication for Ocaliva to include treating liver fibrosis due to non-alcoholic steatohepatitis (NASH). This is a common condition caused by fatty buildups in the liver. The company says that 16 million people worldwide have fibrosis due to NASH. There are no FDA-approved treatments for the disease; the company hopes Ocaliva will be the first. The FDA has set a target action date of June 26 to complete its review of the application.   

stages of liver disease

Image source: Getty Images

Will NASH make Ocaliva a blockbuster?

Some estimates peg the market opportunity in NASH drugs at $35 billion a year. Excitement about the possibility that Intercept would have a chance to address that need sent its stock into the stratosphere in 2014, up to $485 a share, after the company reported positive phase 2 results in its Ocaliva study. However, it's been all downhill since then, with the company's stock dropping all the way down to $93 a share six years later. 

In early data from its phase 3 NASH trial, the company reported that 23% of patients receiving the higher dose of Ocaliva had fibrosis improvement, versus 12% in the placebo group. With those numbers, it is likely that this new indication for the drug will be approved by the FDA. However, it is also likely that the level of adverse events associated with Ocaliva might limit the drug's appeal. Over half the patients taking the drug reported chronic itching.

Intercept's stock was down just over 1% at noon EST Tuesday.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.